{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:02:20Z","timestamp":1772820140845,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T00:00:00Z","timestamp":1423526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12891-015-0489-2","type":"journal-article","created":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T18:10:28Z","timestamp":1423505428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy of anti\u2013tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta\u2013analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Dan","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan-Nan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Xin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"key":"489_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.berh.2006.02.001","volume":"20","author":"J Sieper","year":"2006","unstructured":"Sieper J, Rudwaleit M, Khan MA, Braun J. Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol. 2006;20:401\u201317.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"489_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3346\/jkms.2002.17.5.669","volume":"17","author":"JH Lee","year":"2002","unstructured":"Lee JH, Jun JB, Jung S, Bae SC, Yoo DH, Kim TY, et al. Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci. 2002;17:669\u201373.","journal-title":"J Korean Med Sci"},{"key":"489_CR3","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/ard.2006.064543","volume":"66","author":"B Vander Cruyssen","year":"2007","unstructured":"Vander Cruyssen B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis. 2007;66:1072\u20137.","journal-title":"Ann Rheum Dis"},{"key":"489_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","volume":"48","author":"D Elewaut","year":"2009","unstructured":"Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford). 2009;48:1029\u201335.","journal-title":"Rheumatology (Oxford)"},{"key":"489_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3949\/ccjm.72.4.329","volume":"72","author":"RA Hajj-Ali","year":"2005","unstructured":"Hajj-Ali RA, Lowder C, Mandell BF. Uveitis in the internist\u2019s office: are a patient\u2019s eye symptoms serious? Cleve Clin J Med. 2005;72:329\u201339.","journal-title":"Cleve Clin J Med"},{"key":"489_CR6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0889-857X(21)00714-6","volume":"18","author":"JT Rosembaum","year":"1992","unstructured":"Rosembaum JT. Acute uveitis and spondyloarthropathies. Rheum Dis Clin North Am. 1992;18:143\u201351.","journal-title":"Rheum Dis Clin North Am"},{"key":"489_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:65\u201373.","journal-title":"Ann Rheum Dis"},{"key":"489_CR8","first-page":"1277","volume":"30","author":"S Mu\u00f1oz-Fern\u00e1ndez","year":"2003","unstructured":"Mu\u00f1oz-Fern\u00e1ndez S, Hidalgo V, Fern\u00e1ndez-Mel\u00f3n J, Schlincker A, Bonilla G, Ruiz-Sancho D, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003;30:1277\u20139.","journal-title":"J Rheumatol"},{"key":"489_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/rheumatology\/kes186","volume":"52","author":"G Simonini","year":"2013","unstructured":"Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52:825\u201331.","journal-title":"Rheumatology (Oxford)"},{"key":"489_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1185\/030079903125002847","volume":"20","author":"V P\u00e9rez-Guijo","year":"2004","unstructured":"P\u00e9rez-Guijo V, Santos-Lacomba M, S\u00e1nchez-Hern\u00e1ndez M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Est\u00e9vez E. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004;20:155\u20137.","journal-title":"Curr Med Res Opin"},{"key":"489_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, R\u00f8devand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696\u2013701.","journal-title":"Ann Rheum Dis"},{"key":"489_CR12","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447\u201351.","journal-title":"Arthritis Rheum"},{"key":"489_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.2010.224154","volume":"60","author":"C Mowat","year":"2011","unstructured":"Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571\u2013607.","journal-title":"Gut"},{"key":"489_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1756283X11405250","volume":"4","author":"C Williams","year":"2011","unstructured":"Williams C, Panaccione R, Ghosh S, Rioux K. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol. 2011;4:237\u201348.","journal-title":"Therap Adv Gastroenterol"},{"key":"489_CR15","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/art.22669","volume":"57","author":"J Braun","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007;57:639\u201347.","journal-title":"Arthritis Rheum"},{"key":"489_CR16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896\u2013904.","journal-title":"Ann Rheum Dis"},{"key":"489_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0065-2776(08)60891-3","volume":"64","author":"M Feldmann","year":"1997","unstructured":"Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti\u2011tumor necrosis factor- alpha therapy of rheumatoid arthritis. Adv Immunol. 1997;64:283\u2013350.","journal-title":"Adv Immunol"},{"key":"489_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5694\/j.1326-5377.2005.tb06998.x","volume":"183","author":"PT Nash","year":"2005","unstructured":"Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust. 2005;183:205\u20138.","journal-title":"Med J Aust"},{"key":"489_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40265-013-0009-3","volume":"73","author":"ED Deeks","year":"2013","unstructured":"Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73:75\u201397.","journal-title":"Drugs"},{"key":"489_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor(p75)\u2011Fc fusion protein. N Engl J Med. 1997;337:141\u20137.","journal-title":"N Engl J Med"},{"key":"489_CR21","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00296-009-1157-3","volume":"30","author":"AR Giardina","year":"2010","unstructured":"Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli MC, Principato A, et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int. 2010;30:1437\u201340.","journal-title":"Rheumatol Int"},{"key":"489_CR22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","volume":"71","author":"J Braun","year":"2012","unstructured":"Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis. 2012;71:878\u201384.","journal-title":"Ann Rheum Dis"},{"key":"489_CR23","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","volume":"50","author":"X Baraliakos","year":"2011","unstructured":"Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8\u00a0years\u2013early clinical response predicts long-term outcome. Rheumatology (Oxford). 2011;50:1690\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"489_CR24","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"J Braun","year":"2011","unstructured":"Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011;63:1543\u201351.","journal-title":"Arthritis Rheum"},{"key":"489_CR25","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2011-200358","volume":"71","author":"J Sieper","year":"2012","unstructured":"Sieper J, van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL. Early response to adalimumab predicts long-term remission through 5\u00a0years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:700\u20136.","journal-title":"Ann Rheum Dis"},{"key":"489_CR26","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","volume":"33","author":"MA Machado","year":"2013","unstructured":"Machado MA, Barbosa MM, Almeida AM, de Ara\u00fajo VE, Kakehasi AM, Andrade EI, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 2013;33:2199\u2013213.","journal-title":"Rheumatol Int"},{"key":"489_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000051263","volume":"12","author":"M Oremus","year":"2001","unstructured":"Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer\u2019s disease drug trials. Dement Geriatr Cogn Disord. 2001;12:232\u20136.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"489_CR28","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"489_CR29","unstructured":"Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). [http:\/\/handbook.cochrane.org\/]."},{"key":"489_CR30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"489_CR31","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136\u201346.","journal-title":"Arthritis Rheum"},{"key":"489_CR32","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J, Haibel H, S\u00f6rensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48:1667\u201375.","journal-title":"Arthritis Rheum"},{"key":"489_CR33","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis Jr JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230\u20136.","journal-title":"Arthritis Rheum"},{"key":"489_CR34","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1136\/ard.2006.056747","volume":"65","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, et al. Etanercept 50\u00a0mg once weekly is as effective as 25\u00a0mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:1572\u20137.","journal-title":"Ann Rheum Dis"},{"key":"489_CR35","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187\u201393.","journal-title":"Lancet"},{"key":"489_CR36","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/ard.2004.022582","volume":"64","author":"H Marzo-Ortega","year":"2005","unstructured":"Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O\u2019connor P, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis. 2005;64:1568\u201375.","journal-title":"Ann Rheum Dis"},{"key":"489_CR37","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis Jr JC, Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402\u201312.","journal-title":"Arthritis Rheum"},{"key":"489_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39\u201347.","journal-title":"Ann Rheum Dis"},{"key":"489_CR39","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/ard.2006.052092","volume":"65","author":"S Guignard","year":"2006","unstructured":"Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondyloarthropathy: a retrospective study. Ann Rheum Dis. 2006;65:1631\u20134.","journal-title":"Ann Rheum Dis"},{"key":"489_CR40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.semarthrit.2010.05.008","volume":"40","author":"E Pato","year":"2011","unstructured":"Pato E, Mu\u00f1oz-Fern\u00e1ndez S, Francisco F, Abad MA, Maese J, Ortiz A, et al. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. 2011;40:314\u201323.","journal-title":"Semin Arthritis Rheum"},{"key":"489_CR41","first-page":"865","volume":"29","author":"S D\u2019Angelo","year":"2011","unstructured":"D\u2019Angelo S, Palazzi C, Cantini F, Lubrano E, Marchesoni A, Mathieu A, et al. Etanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issues. Clin Exp Rheumatol. 2011;29:865\u201370.","journal-title":"Clin Exp Rheumatol"},{"key":"489_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","volume":"41","author":"D Wendling","year":"2011","unstructured":"Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41:503\u201310.","journal-title":"Semin Arthritis Rheum"},{"key":"489_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0165-5728(94)90144-9","volume":"55","author":"S Savion","year":"1994","unstructured":"Savion S, Oddo S, Grover S, Caspi RR. Uveitogenic T lymphocytes in the rat: pathogenicity vs. lymphokine production, adhesion molecules and surface antigen expression. J Neuroimmunol. 1994;55:35\u201344.","journal-title":"J Neuroimmunol"},{"key":"489_CR44","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/art.22669","volume":"57","author":"J Braun","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007;57:639\u201347.","journal-title":"Arthritis Rheum"},{"key":"489_CR45","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088\u201394.","journal-title":"Gastroenterology"},{"key":"489_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/ard.62.1.74","volume":"62","author":"H Marzo-Ortega","year":"2003","unstructured":"Marzo-Ortega H, McGonagle D, O\u2019Connor P, Emery P. Efficacy of etanercept for treatment of Crohn\u2019s related spondyloarthritis but not colitis. Ann Rheum Dis. 2003;62:74\u20136.","journal-title":"Ann Rheum Dis"},{"key":"489_CR47","first-page":"532","volume":"35","author":"IH Song","year":"2008","unstructured":"Song IH, Appel H, Haibel H, Loddenkemper C, Braun J, Sieper J, et al. New onset of Crohn\u2019s disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol. 2008;35:532\u20136.","journal-title":"J Rheumatol"},{"key":"489_CR48","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/09546634.2011.646939","volume":"24","author":"A Kyriakou","year":"2013","unstructured":"Kyriakou A, Patsatsi A, Sotiriadis D. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study. J Dermatolog Treat. 2013;24:162\u20138.","journal-title":"J Dermatolog Treat"},{"key":"489_CR49","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa030409","volume":"349","author":"CL Leonardi","year":"2003","unstructured":"Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014\u201322.","journal-title":"N Engl J Med"},{"key":"489_CR50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semarthrit.2007.05.004","volume":"37","author":"B Grinblat","year":"2008","unstructured":"Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum. 2008;37:251\u20135.","journal-title":"Semin Arthritis Rheum"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-015-0489-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-015-0489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-015-0489-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-015-0489-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:04:15Z","timestamp":1630569855000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-015-0489-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,10]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1186\/s12891-015-0489-2","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,10]]},"assertion":[{"value":"15 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"19"}}